News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 650 results
October 2015
-
Media Release
FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
- Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and… -
Media Release
FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
-
Media Release
Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
As part of Q3 Earnings, Novartis announced that it reached a settlement in principle in the suit related to the Company's interactions with specialty pharmacies. Some media coverage did not… -
Media Release
Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
September 2015
-
Media Release
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
-- In the FUTURE 1 study, secukinumab met the primary endpoint showing statistically significant efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA)-- All pre-… -
Media Release
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
-
Media Release
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + MekinistTafinlar + Mekinist combination also demonstrated… -
Media Release
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
-
Media Release
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
- First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and… -
Media Release
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
July 2015
-
Media Release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
- Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable(1)- Basal cell carcinoma, the most common form of skin… -
Media Release
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Pagination
- ‹ Previous page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- …
- 55
- › Next page